Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fenpiverinium→

Fenpiverinium PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
258329-46-3
Molecular formula
C22H29N2O+
Molecular weight
337.5 g/mol
Drug class
Quaternary ammonium antimuscarinicantispasmodic component of fixed-dose analgesic combinations
Mechanism of action
Antagonises muscarinic acetylcholine receptors in visceral smooth muscle, reducing cholinergic tone and intestinal, biliary and urinary tract spasm. It is commonly used in combination with metamizole and pitofenone rather than as a stand-alone product.
Indications / reported uses
  • Component of fixed-dose combinations used for short-term symptomatic relief of painful gastrointestinal, biliary or urinary smooth-muscle spasm, where authorised.

Sources: https://pubmed.ncbi.nlm.nih.gov/6719639/ · https://www.rlsnet.ru/active-substance/metamizol-natriya-pitofenon-fenpiveriniya-bromid-246 · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Quaternary ammonium antimuscarinic; antispasmodic component of fixed-dose analgesic combinations

Mechanism of action

Antagonises muscarinic acetylcholine receptors in visceral smooth muscle, reducing cholinergic tone and intestinal, biliary and urinary tract spasm. It is commonly used in combination with metamizole and pitofenone rather than as a stand-alone product.

General use cases

  • Component of fixed-dose combinations used for short-term symptomatic relief of painful gastrointestinal, biliary or urinary smooth-muscle spasm, where authorised.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Fenpiverinium PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fenpiverinium Permitted Daily Exposure (PDE) report (the Fenpiverinium PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fenpiverinium Occupational Exposure Limit (OEL) report (the Fenpiverinium OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.